Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jpc.1_13917 | DOI Listing |
J Invest Dermatol
February 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada; Division of Dermatology, Women's College Hospital, Toronto, Canada. Electronic address:
COVID-19 skin manifestations are multifaceted, ranging from urticaria, morbilliform or papulovesicular rash, livedoid purpuric lesions, and to pseudochilblains (also called COVID toes). Recent insights into the mechanism of these manifestations have highlighted that morbilliform, papulovesicular, and livedoid/purpuric rashes are related to virus-induced endothelial cell damage and linked to moderate-to-severe disease, whereas pseudochilblains are related to an exaggerated IFN-1 production by plasmacytoid dendritic cells in protected individuals. In this paper, we will review the clinical and physiopathological features of cutaneous COVID-19 manifestations in relation to the direct viral cytopathic effects and dysregulated IFN-1 responses.
View Article and Find Full Text PDFCureus
April 2024
Internal Medicine, Saint Peter's University Hospital, New Brunswick, USA.
J Dtsch Dermatol Ges
May 2024
Department of Dermatology and Venereology, Faculty of Medicine, University of Cologne, and University Hospital of Cologne, Cologne, Germany.
Cureus
March 2024
Dermatology, Near East University, Faculty of Medicine, Nicosia, CYP.
COVID-19 is a global pandemic that started in 2020. During the pandemic, patients have presented with various cutaneous manifestations of COVID-19 infections. Currently, COVID-19 infections are still present worldwide, although to a lesser extent.
View Article and Find Full Text PDFCureus
February 2024
Dermatology, Family Dermatology of North Florida, Tallahassee, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!